Clinical Trial Update: Iscar for Supplemental Care in Stage IV Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Iscar as supplemental care for stage IV lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Iscar

Snippet

Sponsor: National Center for Complementary and Integrative Health (NCCIH) | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED